3210 Merryfield Row
About Abilita BioAbilita Bio was founded in June 2014 and is an innovation-driven biotechnology company focused on enabling discovery and development of drugs targeting challenging membrane proteins, including G Protein-Coupled Receptors (GPCRs) and ion channels.
Founder and CEO: Mauro Mileni, PhD
COO: Randy Schreckhise
CTO: Rosario Billetta, DSc
Vice President, Innovation: Christopher B. Roth, PhD
Please click here for Ablita Bio job opportunities.
Please click here for Abilita Bio's pipeline.
7 articles with Abilita Bio
Abilita Bio, Inc., today announced the appointment of Daniel M. Bradbury to its Board of Directors.
Abveris and Abilita Bio Announce a Discovery Collaboration to Develop Therapeutics for Challenging Membrane Protein Targets
Abveris, Inc. ("Abveris") and Abilita Bio, Inc. announce a joint research collaboration that will leverage the synergies between their platforms to enable the discovery of novel antibodies targeting key GPCRs within the tumor immune microenvironment.
Abilita Bio Announces Business Growth and Key DevelopmentsShift to discovery of proprietary programs facilitated by increased resources, infrastructure and capabilities
Abilita Bio, Inc., an innovation-driven biotechnology company focused on enabling discovery and development of drugs targeting challenging membrane proteins, today announced a series of corporate updates that includes an expansion of scientific scope, personnel, and infrastructure.
Research collaboration will focus on the generation of novel Enabled Membrane Proteins (EMPs™) to support R&D efforts on challenging drug targets
Under the terms of the agreement, Abilita will generate EMPs for several high-value GPCR and ion-channel targets, which will be screened by X-Chem using its proprietary DEX libraries to identify agonists and/or antagonists, as dictated by the target biology and desired mechanism of action.
Abilita Bio Signs A New Research Collaboration With A Global Pharmaceutical Company And 2016 Milestone Review
Abilita Bio Awarded NCI Phase-I SBIR Grant To Develop Therapeutic Antibodies Targeting Metastatic Breast Cancer